List of Excipients in Branded Drug XTAMPZA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Collegium Pharmaceutical Inc	XTAMPZA	oxycodone	24510-110	CARNAUBA WAX	2028-10-09
Collegium Pharmaceutical Inc	XTAMPZA	oxycodone	24510-110	FERRIC OXIDE YELLOW	2028-10-09
Collegium Pharmaceutical Inc	XTAMPZA	oxycodone	24510-110	HYPROMELLOSE	2028-10-09
Collegium Pharmaceutical Inc	XTAMPZA	oxycodone	24510-110	MAGNESIUM STEARATE	2028-10-09
Collegium Pharmaceutical Inc	XTAMPZA	oxycodone	24510-110	MYRISTIC ACID	2028-10-09
Collegium Pharmaceutical Inc	XTAMPZA	oxycodone	24510-110	PEG-32 STEARATE	2028-10-09

XTAMPZA ER Excipient Strategy and Commercial Opportunities

Last updated: August 23, 2026

XTAMPZA ER is an extended-release oxycodone product built around Collegium Pharmaceutical’s DETERx multiparticulate technology. Its commercial value comes from the interaction between oxycodone, lipidic and polymeric excipient systems, capsule-based dosing flexibility, and abuse-deterrence claims supported by FDA labeling. The strategy creates opportunities in lifecycle management, hospital and specialty-pharmacy distribution, international licensing, and platform applications for other controlled substances.

What is XTAMPZA ER and how does its formulation work?

XTAMPZA ER is an oral extended-release formulation of oxycodone indicated for the management of severe pain requiring continuous, around-the-clock opioid treatment when alternatives are inadequate.[1] FDA approved the product in June 2016 under NDA 208090.[2]

The product uses DETERx microspheres. Each microsphere contains oxycodone in a controlled-release matrix designed to maintain extended release after common physical manipulation. The microspheres are filled into capsules and can also be administered by sprinkling the contents over soft food or into a cup, which supports patients who have difficulty swallowing intact capsules.[1]

Core formulation architecture

Formulation element	Commercial or technical function
Oxycodone active pharmaceutical ingredient	Provides opioid analgesic activity
Lipidic excipient or matrix components	Help embed oxycodone and control drug release
Polymer and cellulosic excipients	Provide structural integrity and release control
Glidants and lubricants	Support microsphere manufacture and capsule filling
Hard gelatin capsule	Enables unit-dose delivery and sprinkle administration
Colorants and capsule-shell materials	Support product identification and dose differentiation

The formulation is intended to preserve extended release when the capsule is chewed or the microspheres are physically disrupted. The FDA label states that XTAMPZA ER maintains extended release when chewed, although chewing the product increases oxycodone exposure and may produce potentially fatal overdose.[1]

The abuse-deterrent designation does not eliminate misuse risk. It means the formulation has properties that may deter certain routes or methods of abuse, particularly crushing and extraction-based manipulation. XTAMPZA ER remains a Schedule II opioid with substantial safety and regulatory obligations.[1]

What excipients protect the XTAMPZA ER commercial model?

The commercial protection is unlikely to depend on a single inactive ingredient. It is based on a coordinated excipient system, particle architecture, manufacturing process, and performance profile.

Lipid-based release control

Lipidic excipients can reduce the immediate availability of oxycodone by embedding the drug in a hydrophobic matrix. The matrix can slow water penetration and drug diffusion while maintaining processability during microsphere formation.

For controlled-release opioids, lipid selection affects:

• Drug loading
• Release rate
• Particle strength
• Chew resistance
• Extraction resistance
• Food-effect behavior
• Batch-to-batch reproducibility

The most valuable excipient claims usually cover the relationship between the active ingredient and the matrix rather than the use of a commodity excipient in isolation.

Polymer and cellulosic structure

Polymeric components can improve mechanical integrity and control hydration. Cellulosic excipients can also improve powder flow, capsule filling, and microsphere handling. The formulation must balance opposing requirements: particles must be durable enough to deter manipulation but capable of releasing oxycodone predictably in the gastrointestinal tract.

Manufacturing-function excipients

Glidants, lubricants, and surface modifiers have a direct effect on manufacturing economics. Their selection can influence:

• Microsphere yield
• Equipment fouling
• Capsule-fill weight variation
• Content uniformity
• Dissolution profile
• Storage stability
• Scale-up performance

A substitute excipient that appears pharmaceutically equivalent may still create a regulatory or patent problem if it changes particle morphology, release kinetics, or abuse-deterrence performance.

Capsule-shell strategy

The capsule format provides a separate lifecycle advantage. XTAMPZA ER can be administered as intact capsules or as sprinkled microspheres. This supports patient populations with swallowing difficulty without requiring a new dosage form.

Capsule-shell changes can affect:

• Moisture transfer
• Stability
• Dissolution
• Identification
• Dose administration instructions
• Compatibility with automated dispensing systems

A generic developer would need to assess the capsule shell, fill material, microsphere properties, and administration method as an integrated product rather than treating the capsule as a conventional container.

What FDA regulatory status does XTAMPZA ER have?

XTAMPZA ER is an FDA-approved NDA product and is listed in the FDA Orange Book. It is an abuse-deterrent opioid formulation, but abuse-deterrent labeling does not create a separate exclusivity period comparable to new chemical entity exclusivity.[1][3]

Regulatory item	Status
Product	XTAMPZA ER
Active ingredient	Oxycodone
Dosage form	Extended-release oral capsules
Sponsor	Collegium Pharmaceutical, Inc.
FDA pathway	NDA 208090
Approval date	June 2016
Controlled-substance class	Schedule II opioid
Abuse-deterrent status	Labeled as abuse-deterrent by physical and chemical properties
Generic pathway	ANDA, subject to Orange Book patent and exclusivity issues

XTAMPZA ER did not receive five-year new chemical entity exclusivity because oxycodone was already an established active ingredient. Its market protection therefore depends heavily on formulation patents, regulatory exclusivity where applicable, trade secrets, manufacturing know-how, and commercial execution.

What patents protect XTAMPZA ER?

XTAMPZA ER has been protected by patents directed to abuse-deterrent oxycodone formulations, controlled-release matrices, multiparticulate dosage forms, and related manufacturing concepts. The relevant patent estate has included Collegium-associated patents and earlier DETERx technology rights.

Public patent records have associated XTAMPZA ER with U.S. patents including:

Patent	General subject matter	Strategic relevance
US 8,808,741	Abuse-deterrent extended-release opioid formulation technology	Foundational formulation protection
US 9,763,933	Abuse-deterrent oxycodone formulation technology	Composition and performance protection
US 10,610,488	Extended-release opioid formulation technology	Later-generation protection
Other later-issued patents	Formulation, dosing, and manufacturing aspects	Potential blocking or supplemental coverage

Patent scope and enforceability depend on claim language, terminal disclaimers, prosecution history, Orange Book listing, and litigation outcomes. Patent expiration dates may also be adjusted by patent-term adjustment, patent-term extension, or terminal-disclaimer restrictions. A commercial assessment should therefore distinguish between the earliest possible loss of protection and the latest listed expiry date.

What type of claims matter most?

The most commercially important claims are likely to be those covering:

1. Oxycodone embedded in a defined abuse-deterrent matrix.
2. Multiparticulate microspheres with specified release behavior.
3. Physical properties that survive crushing or chewing.
4. Methods of administering oxycodone using the microsphere contents.
5. Manufacturing processes that produce the required particle structure.
6. Formulations with defined drug-to-excipient ratios.
7. Food-compatible or sprinkle-compatible dosage forms.

A narrow claim covering a particular excipient ratio may be less valuable than a broader claim covering the functional structure of the microsphere. Conversely, a narrow formulation claim can become important if it is difficult for an ANDA applicant to design around while maintaining bioequivalence and abuse-deterrent performance.

When does XTAMPZA ER lose exclusivity?

XTAMPZA ER’s effective exclusivity is determined by several layers rather than one date.

Commercial exclusivity timeline

Event	Timing
FDA approval	June 2016
Five-year NCE exclusivity	Not applicable because oxycodone was previously approved
Formulation and abuse-deterrence patents	Extend beyond initial approval and vary by patent
ANDA challenge risk	Depends on listed patents and Paragraph IV certifications
Generic launch	Could occur after patent resolution, settlement permission, or successful invalidity/noninfringement litigation

The product’s practical loss of exclusivity may occur before every patent expires if a competitor launches after defeating key patents or obtains a settlement date. It may occur after the earliest patent expiry if later patents remain enforceable and difficult to design around.

What Paragraph IV challenges and litigation affect XTAMPZA ER?

An ANDA applicant can challenge Orange Book-listed patents through a Paragraph IV certification. The patent owner can then file suit within 45 days, potentially triggering a 30-month stay of ANDA approval under the Hatch-Waxman framework.[4]

For XTAMPZA ER, litigation risk centers on whether a generic applicant can:

• Avoid the asserted formulation claims.
• Demonstrate bioequivalence without copying protected microsphere characteristics.
• Challenge written description, enablement, obviousness, or anticipation.
• Dispute whether a patent is properly listed in the Orange Book.
• Obtain approval for a different abuse-deterrent design.
• Establish that its product does not infringe process or composition claims.

The high technical burden is important. A generic oxycodone extended-release capsule cannot necessarily substitute conventional beads or a standard hydrophilic matrix and expect equivalent clinical performance. XTAMPZA ER’s labeling, sprinkle instructions, extended-release behavior, and abuse-deterrent characteristics create multiple development constraints.

How strong is the XTAMPZA ER patent estate?

The estate is commercially stronger than a single formulation patent but remains exposed to standard generic challenges.

Strengths

• The product uses a differentiated multiparticulate architecture.
• The abuse-deterrent profile is linked to formulation performance.
• The capsule contents can be administered by sprinkling, adding a dosage-form and administration dimension.
• Manufacturing conditions may be difficult to reproduce without process knowledge.
• Controlled-release and abuse-deterrent claims can create several potential infringement theories.

Weaknesses

• Oxycodone itself is an old and widely understood active ingredient.
• Many relevant excipients are available from multiple suppliers.
• Generic developers can pursue nonidentical matrix designs.
• Abuse-deterrent claims may face obviousness challenges based on prior opioid formulations.
• Functional claims may raise enablement or claim-construction disputes.
• A successful noninfringing design could reduce the practical value of composition claims.

The strongest protection is likely the combination of formulation claims and manufacturing know-how. Trade secrets covering particle formation, mixing order, temperature control, solvent use, coating, drying, and quality-control limits can remain valuable after patent expiry, although they cannot prevent independent development.

What formulation patents could generic developers design around?

A generic developer might pursue one of four strategies:

Conventional extended-release matrix

A developer could use a hydrophilic polymer matrix or conventional coated beads. This may reduce infringement risk but create bioequivalence and abuse-deterrence challenges.

Alternative lipid system

Replacing one lipid or fatty-acid component with another may avoid a narrow composition claim. The substitute must still deliver comparable release, stability, and manipulation resistance.

Different multiparticulate geometry

The developer could change particle size, layering, coating thickness, porosity, or drug distribution. These changes may affect food-effect results and capsule-content uniformity.

Different administration profile

A competitor could avoid the sprinkle claim set by seeking approval only for intact-capsule administration. That approach could limit commercial differentiation and reduce substitutability in patients who cannot swallow capsules.

Design-around activity is more likely to produce a product with a different abuse-deterrent profile than an exact XTAMPZA ER copy. The FDA may require comparative in vitro manipulation studies and human pharmacokinetic data depending on the proposed product and labeling.[5]

What excipient opportunities exist beyond XTAMPZA ER?

XTAMPZA ER creates licensing and product-development opportunities for excipient suppliers, contract development organizations, and specialty pharmaceutical companies.

Excipient supplier opportunities

Suppliers can target excipients that provide:

• Higher drug loading
• Lower processing temperatures
• Better oxidative stability
• Improved capsule compatibility
• Lower dissolution variability
• Improved resistance to alcohol-induced dose dumping
• Reduced dependence on a single-source material

A supplier with a qualified alternative to a critical lipid, polymer, or processing aid could create value if the alternative preserves the product’s release profile and abuse-deterrent properties.

Platform licensing

The DETERx approach may be adapted to other controlled substances, including:

• Hydromorphone
• Morphine
• Methylphenidate
• Amphetamine products
• Buprenorphine
• Other drugs with abuse or dose-dumping concerns

The main opportunity is not simple excipient substitution. It is adaptation of the particle architecture, release-control mechanism, and manufacturing process to a new active ingredient.

Reformulation opportunities

Potential lifecycle products include:

• Lower-dose capsules
• Pediatric or geriatric dose presentations where appropriate
• Sprinkle-ready sachets
• Smaller capsules
• Combination products
• Hospital-use presentations
• International formulations using locally accepted excipients

Each product would require a separate regulatory and patent analysis. A reformulation can extend commercial life only if it creates meaningful clinical or operational value and has protectable claims.

How does XTAMPZA ER compare with competing opioid formulations?

Product	Active ingredient	Core technology	Differentiation
XTAMPZA ER	Oxycodone	DETERx multiparticulate microspheres	Sprinkle administration and abuse-deterrent properties
OxyContin OP	Oxycodone	Abuse-deterrent solid dosage form	Widely recognized abuse-deterrent oxycodone benchmark
Hysingla ER	Hydrocodone	Abuse-deterrent tablet	Hard tablet and extended-release hydrocodone
ALO-02	Oxycodone/naloxone	Abuse-deterrent combination approach	Pharmacologic antagonist strategy
Generic oxycodone ER	Oxycodone	Various conventional matrices	Lower-cost substitution where approved

XTAMPZA ER’s main product-level advantage is flexibility of administration. Its main commercial disadvantage is competition from established oxycodone products, generic opioid alternatives, payer controls, and the broader reduction in opioid prescribing.

What revenue exposure does XTAMPZA ER create?

XTAMPZA ER is commercially important to Collegium because the company has built its portfolio around specialty pain products and abuse-deterrent formulations. Revenue exposure depends on:

• Net price after rebates
• Commercial and government formulary access
• Opioid prescribing volumes
• Generic oxycodone competition
• Patent settlements
• State-level opioid restrictions
• Prescriber adoption of abuse-deterrent products
• Patient copay and prior-authorization requirements

The addressable market is narrower than the total oxycodone market because XTAMPZA ER is intended for patients requiring continuous opioid therapy. However, the product can command a differentiated position when prescribers value abuse-deterrent labeling, sprinkle administration, or a specific oxycodone formulation.

A generic entrant would likely pursue a staged launch:

1. Initial limited distribution through specialty or controlled-substance channels.
2. Pricing below XTAMPZA ER while preserving a premium over conventional oxycodone ER.
3. Payer-driven substitution where the generic obtains preferred formulary status.
4. Expansion after additional strengths and dosage forms receive approval.

What generic entry risks exist for XTAMPZA ER?

The principal risks are:

• A successful Paragraph IV challenge to key formulation patents.
• A noninfringing generic with comparable pharmacokinetics.
• Patent expiration without a commercially meaningful settlement barrier.
• Payer pressure favoring lower-cost oxycodone products.
• Reduced opioid utilization.
• A competing abuse-deterrent opioid with better reimbursement.
• Regulatory changes affecting opioid labeling or distribution.
• Loss of manufacturing exclusivity through independent process development.

The most disruptive scenario would be a generic that matches the core clinical use of XTAMPZA ER while avoiding the most valuable patent claims. A less disruptive scenario would be a limited generic with fewer strengths, no sprinkle indication, or a different abuse-deterrent label.

What licensing and partnership opportunities are available?

Commercial opportunities exist at three levels.

Product licensing

A company with an abuse-deterrent opioid or controlled-release formulation can license the platform for a new active ingredient or geographic market. Royalty value would depend on patent term, regulatory status, manufacturing transferability, and local opioid-market restrictions.

Manufacturing partnerships

Specialized contract manufacturers could offer:

• Microsphere production
• Encapsulation
• Controlled-release dissolution testing
• Abuse-deterrence manipulation studies
• Scale-up and process validation
• Stability programs

The principal barrier is not capsule filling. It is reproducing the particle structure and dissolution profile at commercial scale.

Excipient partnerships

An excipient supplier could seek qualification as a second source or develop a functionally equivalent material. The supplier would need to demonstrate consistent particle morphology, impurity control, stability, and regulatory acceptability.

What geographic coverage applies to XTAMPZA ER?

XTAMPZA ER is primarily a U.S. commercial product. International expansion would require country-specific regulatory filings, opioid scheduling review, controlled-substance distribution licenses, and local patent analysis.

International opportunities may be constrained by:

• Different abuse-deterrent labeling standards
• Country-specific opioid prescribing controls
• Local reference-product requirements
• Import and controlled-substance restrictions
• National reimbursement systems
• Local excipient acceptance
• Patent rights that differ from the U.S. estate

A global strategy could use the same DETERx technical platform while adjusting capsule shell materials, excipient specifications, manufacturing sites, and labeling.

Key Takeaways

• XTAMPZA ER’s differentiation is based on DETERx multiparticulate microspheres, not a single excipient.
• The formulation combines controlled release, physical manipulation resistance, and sprinkle administration.
• Oxycodone is an established active ingredient, so formulation patents and manufacturing know-how are central to exclusivity.
• Generic developers face formulation, bioequivalence, abuse-deterrence, and patent-design-around barriers.
• Excipient commercial opportunities include alternative lipid systems, polymer optimization, second sourcing, and platform adaptation.
• The highest-value IP is likely the combined formulation and manufacturing system.
• Generic entry could occur through patent litigation, settlement, design-around development, or post-expiry launch.
• Commercial exposure is shaped by payer access, opioid prescribing trends, controlled-substance regulation, and the strength of later-issued formulation patents.

FAQs

Can XTAMPZA ER excipients be replaced without creating a new product?

Usually not without development and regulatory consequences. A replacement may change dissolution, food effect, stability, capsule compatibility, and abuse-deterrent performance.

Is XTAMPZA ER an abuse-proof opioid?

No. It is labeled as abuse-deterrent, but the product remains capable of misuse, overdose, addiction, and diversion.[1]

Does XTAMPZA ER have new chemical entity exclusivity?

No. Oxycodone was previously approved. XTAMPZA ER relies primarily on formulation patents, regulatory protections applicable to the NDA, trade secrets, and commercial differentiation.

Can a generic oxycodone extended-release product automatically substitute for XTAMPZA ER?

No. Substitution depends on FDA approval, therapeutic-equivalence designation, state law, payer policy, and whether the generic is approved for the same dosage form and indications.

What is the most defensible lifecycle strategy for XTAMPZA ER?

The strongest strategy is a combination of later-generation formulation patents, manufacturing-process protection, differentiated administration options, additional controlled-substance applications, and evidence supporting payer and prescriber preference.

References

1. Collegium Pharmaceutical, Inc. (2023). XTAMPZA ER (oxycodone) extended-release capsules, prescribing information. U.S. Food and Drug Administration labeling database.

2. U.S. Food and Drug Administration. (2016). FDA approves extended-release oxycodone product with abuse-deterrent properties. FDA.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.

4. U.S. Government Publishing Office. (2024). 21 U.S.C. § 355: New drugs and antibiotics. United States Code.

5. U.S. Food and Drug Administration. (2015). Abuse-deterrent opioids: Evaluation and labeling guidance for industry. FDA.